Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
A retrospective study was performed to collect information regarding efficacy and toxicity of cidofovir (CDV) in allogeneic stem cell transplant patients. Data were available on 82 patients. The indications for therapy were cytomegalovirus (CMV) disease in 20 patients, primary preemptive therapy in 24 patients, and secondary preemptive therapy in 38 patients. Of the patients, 47 had received previous antiviral therapy with ganciclovir, foscarnet, or both drugs. The dosage of CDV was 1 to 5 mg/kg per week followed by maintenance every other week in some patients. The duration of therapy ranged from 1 to 134 days (median, 22 days). All patients received probenecid and prehydration. Ten of 20 (50%) patients who were treated for CMV disease (9 of 16 with pneumonia) responded to CDV therapy, as did 25 of 38 (66%) patients who had failed or relapsed after previous preemptive therapy and 15 of 24 (62%) patients in whom CDV was used as the primary preemptive therapy. Of the patients, 21 (25.6%) developed renal toxicity that remained after cessation of therapy in 12 patients. Fifteen patients developed other toxicities that were potentially due to CDV or the concomitantly given probenecid. No toxicity was seen in 45 (61.6%) patients. Cidofovir can be considered as second-line therapy in patients with CMV disease failing previous antiviral therapy. However, additional studies are needed before CDV can be recommended for preemptive therapy.
Ljungman
P
P
Huddinge University Hospital, Stockholm, Sweden; St Anna Kinderspital, Vienna, Austria. per.ljungman@medhs.ki.se
Deliliers
G L
GL
Platzbecker
U
U
Matthes-Martin
S
S
Bacigalupo
A
A
Einsele
H
H
Ullmann
J
J
Musso
M
M
Trenschel
R
R
Ribaud
P
P
Bornhäuser
M
M
Cesaro
S
S
Crooks
B
B
Dekker
A
A
Gratecos
N
N
Klingebiel
T
T
Tagliaferri
E
E
Ullmann
A J
AJ
Wacker
P
P
Cordonnier
C
C
D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage / Q000592:standards / Q000633:toxicity; D002648:Child; D002675:Child, Preschool; D000077404:Cidofovir; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D003596:Cytosine / Q000008:administration & dosage* / Q000031:analogs & derivatives / Q000592:standards / Q000633:toxicity; D003625:Data Collection; D004341:Drug Evaluation; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000592:standards / Q000633:toxicity; D051437:Renal Insufficiency / Q000139:chemically induced / Q000821:virology; D012189:Retrospective Studies; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir